UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 9, 2023 (June 8, 2023)

AZIYO BIOLOGICS, INC.

(Exact name of registrant as specified in its charter)

12510 Prosperity Drive, Suite 370,
Silver Spring, MD 20904 

(Address of principal executive offices) (Zip Code)

(240) 247-1170 

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02           Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 8, 2023, the stockholders of Aziyo Biologics, Inc. (the “Company”) approved the Aziyo Biologics, Inc. Amended and Restated 2020 Incentive Award Plan (the “Plan”). The material terms of the Plan are summarized in the section captioned “Proposal No. 3 Approval of the Aziyo Biologics, Inc. Amended and Restated 2020 Incentive Award Plan” of the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 27, 2023 (the “Proxy Statement”), which description is incorporated herein by reference.

The foregoing description of the Plan does not purport to be complete and is qualified in its entirety by reference to the full text of the Plan, a copy of which was included as Annex A to the Proxy Statement and is filed as Exhibit 10.1 to this Current Report on Form 8-K.

Item 5.07           Results of Operations and Financial Condition.

On June 8, 2023, the Company held its annual meeting of stockholders. A total of 10,120,917 shares of the Company’s Class A common stock were present in person or represented by proxy at the meeting, representing approximately 85.2% of the Company’s Class A common stock outstanding as of the April 13, 2023 record date. Following are the voting results for the proposals considered and voted upon at the meeting, each of which were described in the Proxy Statement.

Item 1 – Election of two Class III directors to serve until the Company’s annual meeting of stockholders to be held in 2026 and until their respective successors have been duly elected and qualified.

Item 2 – Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023.

Item 3 – Approval of the Aziyo Biologics, Inc. Amended and Restated 2020 Incentive Award Plan.

Based on the foregoing votes, David Colpman and Kevin Rakin were elected as Class III directors, and Items 2 and 3 were approved.

Item 9.01           Financial Statements and Exhibits.

(d)          Exhibits

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.